SCHEMBL390165

SCHEMBL390165

COC(=O)c1ccnc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.60
KDM6B O15054 1/20 0.60
KDM5C P41229 1/20 0.60
KDM4C Q9H3R0 1/20 0.60
KDM2A Q9Y2K7 1/20 0.60
KDM3A Q9Y4C1 1/20 0.60
ALOX15 P16050 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
JMJD6 Q6NYC1 1/20 0.53
HTT P42858 1/20 0.49
ACLY P53396 1/20 0.48
TAS1R3 Q7RTX0 2/20 0.48
TAS1R1 Q7RTX1 2/20 0.48
TAS1R2 Q8TE23 2/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31320054 0.85 KDM4E (0.50) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL14977130 0.82 KDM4E (0.66) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL13847864 0.81 TAS1R3 (0.41) KDM4EKDM6BKDM5CKDM4CKDM2A
Hydrochloric Acid SCHEMBL581820 0.81 KDM4C (0.52) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL29894587 0.81 KDM4E (0.86) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL70279 0.81 KDM4E (0.86) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL4727956 0.81 ATR (0.46) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL27953096 0.81 JMJD6 (0.56) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL10339477 0.81 TAS1R3 (0.51) KDM4EKDM6BKDM5CKDM4CKDM2A
Ethyl-2-Chloropyridine-4-Carboxylate SCHEMBL1425666 0.81 JMJD6 (0.56) KDM5CKDM4CL3MBTL1JMJD6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118843616-A Benzamide compounds for the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-10-25 CN claimed
CN-118307822-B Production process of environment-friendly laminating material 广东美士达药包材料股份有限公司 2024-10-18 CN claimed
CN-118307822-A Production process of environment-friendly laminating material 广东美士达药包材料股份有限公司 2024-07-09 CN claimed
CN-112321494-B Method for preparing 2-chloro-4-isopropylpyridine 上海凌凯医药科技有限公司 2022-04-19 CN claimed
CN-112321494-A Method for preparing 2-chloro-4-isopropylpyridine 上海凌凯医药科技有限公司 2021-02-05 CN claimed
CN-103664766-B Preparation method of 2-aminopyridine-4-methyl alcohol UNIV ZHEJIANG 2015-06-24 CN claimed
CN-103664766-A Preparation method of 2-aminopyridine-4-methyl alcohol UNIV ZHEJIANG 2014-03-26 CN claimed
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 EP disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 US disclosed
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
EP-4702025-A1 BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-03-04 EP disclosed
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 EP disclosed
EP-4076460-B1 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
WO-1992020676-A1 SUBSTITUTED 3-AMINOQUINUCLIDINES PFIZER INC. (US) 1992-11-26 WO disclosed
EP-0254856-B1 PYRIDINETHANOL AMINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1991-09-04 EP disclosed
EP-0434132-A2 Herbicidal acrylonitrile derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-06-26 EP disclosed
US-5010201-A Process for the preparation of substituted 2-chloropyridines BAYER AKTIENGESELLSCHAFT (DE) 1991-04-23 US disclosed
US-4988714-A Drugs for treatment of obesity and diabetics, increases protein breakdown, for fattening animals HOFFMANN-LA ROCHE INC. (US) 1991-01-29 US disclosed
US-4800206-A ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1989-01-24 US disclosed
EP-0254856-A2 Pyridinethanol amine derivatives F. HOFFMANN-LA ROCHE AG (CH) 1988-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 KDM4E 306/4885KDM6B 239/4885KDM5C 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.